Food and Drug Administration repudiates ADHD drug by Sunovion
Sunovion’s ADHD drug for the treatment of attention-deficit hyperactivity disorder (ADHD) has not been accepted by the Food and Drug Administration, FDA. It is so because the drug for ADHD treatment in its current form needs additional clinical trials and data for accessing the efficacy and tolerability of dasotraline. The drug is a novel dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI). Sunovion is slated to meet the Food and Drug Administration for discussing the problems.
Food and Drug Administration backs Shire’s Takhzyro for Hereditary Angioedema
The U.S. Food and Drug Administration a...
